Neuravi is committed to developing clinical data to advance the treatment of stroke.
In 2015, Neuravi launched a prospective pivotal trial, the ARISE II Trial (Analysis of Revascularisation in Ischemic Stroke with EmboTrap®) in clinical centres across the US and Europe. Dr. Sam Zaidat and Prof. Dr. Tommy Andersson are the US and European principal investigators of the study. ARISE II is a single-arm study that will enroll over 2016. Data from the study will be submitted to U.S. Food and Drug Administration (FDA) in support of an application for market clearance for the EmboTrap® Revascularization Device.
To date there has been extensive clinical evaluation of the EmboTrap in Europe. The EmboTrap was one of the devices used to treat patients in the positive ESCAPE trial (Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke). In 2014, Neuravi embarked upon the ARISE trial, a multi-centre European study, which built upon the positive experience of the first-in-human evaluation of the CE-marked EmboTrap Revascularization Device.
Please contact us at email@example.com if you are interested in learning more.